Iodine
Iodine Products
Sold as A-36 · LIPIODOL ULTRA FLUID
- Drug class
- Iodine Products
- Availability
- Over-the-counter
- Routes
- Sublingual, Intracavitary
- Markets covered
- 3
- Products on record
- 4
- FDA reports (12 mo)
- 450
Overview
Plain-language summary, compiled from the cited regulatory records
Iodine is a substance used in a specific drug class: Iodine Products [1]. It is approved for the constitutional treatment of inhalant allergies [1].
This active ingredient is available under various brand names, including A-36 [1]. In the past 12 months, there have been 450 adverse event reports associated with products containing iodine [2]. The most frequently reported reactions in these reports include off-label use, the drug being ineffective, nausea, use in unapproved indications, and rash [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | May 15, 2026 |
| US United States | FDA | 1 | January 9, 2025 |
| CA Canada | Health Canada | 1 | April 10, 2026 |
GBUnited Kingdom· MHRA
2 products
Uses
For use in the pre-operative management of hyperthyroidism.
How to take
USUnited States· FDA
1 product
Uses
INDICATIONS
Constitutional treatment of inhalant allergies.
How to take
CACanada· Health Canada
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Iodine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL002406170 · revised May 15, 2026
- [2]FDA DailyMed · 161c4738-9ead-46… · revised January 9, 2025 [PDF]
- [3]Health Canada (DPD) · 00386685 · revised April 10, 2026
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.